Upfront dose-reduced chemotherapy synergizes with immunotherapy to optimize chemoimmunotherapy in squamous cell lung carcinoma

BACKGROUND: The survival benefits of combining chemotherapy (at the maximum tolerated dose, MTD) with concurrent immunotherapy, collectively referred to as chemoimmunotherapy, for the treatment of squamous cell lung carcinoma (SQCLC) have been confirmed in recent clinical trials. Nevertheless, optim...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Xiran, Du, Yang, Wang, Zhijie, Wang, Xin, Duan, Jianchun, Wan, Rui, Xu, Jiachen, Zhang, Pei, Wang, Di, Tian, Yanhua, Han, Jiefei, Fei, Kailun, Bai, Hua, Tian, Jie, Wang, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7594539/
https://www.ncbi.nlm.nih.gov/pubmed/33115941
http://dx.doi.org/10.1136/jitc-2020-000807

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7594539/
https://www.ncbi.nlm.nih.gov/pubmed/33115941
http://dx.doi.org/10.1136/jitc-2020-000807

Ejemplares similares